参考文献/References:
[1] 《中国心血管健康与疾病报告2020》编写组.《中国心血管健康与疾病报告2020》要点解读[J]. 中国心血管杂志,2021,26(3):209-218.
[2] Seif-Naraghi SB,Singelyn JM,Salvatore MA,et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction[J]. Sci Transl Med,2013,5(173):173ra25.
[3] Creemers EE,Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart[J]. Cardiovasc Res,2011,89(2):265-272.
[4] del Re DP,Amgalan D,Linkermann A,et al. Fundamental mechanisms of regulated cell death and implications for heart disease[J]. Physiol Rev,2019,99(4):1765-1817.
[5] Virag JA,Rolle ML,Reece J,et al. Fibroblast growth factor-2 regulates myocardial infarct repair:effects on cell proliferation,scar contraction,and ventricular function[J]. Am J Pathol,2007,171(5):1431-1440.
[6] Watanabe S,Shite J,Takaoka H,et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure[J]. Eur Heart J,2006,27(7):832-838.
[7] Azeloglu EU,Costa KD. Cross-bridge cycling gives rise to spatiotemporal heterogeneity of dynamic subcellular mechanics in cardiac myocytes probed with atomic force microscopy[J]. Am J Physiol Heart Circ Physiol,2010,298(3):H853-H860.
[8] Berry MF,Engler AJ,Woo YJ,et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance[J]. Am J Physiol Heart Circ Physiol,2006,290(6):H2196-H2203.
[9] 马鑫,张书宁,朱洪,等. 梗死心肌弹性模量与心肌结构及功能的时间依赖性相关变化[J]. 中国分子心脏病学杂志,2014,14(5):1089-1093.
[10] Blom AS,Pilla JJ,Gorman RC 3rd,et al. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep[J]. Heart Fail Rev,2005,10(2):125-139.
[11] Klodell CT Jr,Aranda JM Jr,Mcgiffin DC,et al. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device[J]. J Thorac Cardiovasc Surg,2008,135(1):188-195.
[12] Lietz K,Long JW,Kfoury AG,et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era:implications for patient selection[J]. Circulation,2007,116(5):497-505.
[13] Mantha S,Pillai S,Khayambashi P,et al. Smart hydrogels in tissue engineering and regenerative medicine[J]. Materials(Basel),2019,12(20):3323.
[14] Sakakibara Y,Tambara K,Sakaguchi G,et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor[J]. Eur J Cardiothorac Surg,2003,24(1):105-111; discussion 12.
[15] Frangogiannis NG. Pathophysiology of myocardial infarction[J]. Compr Physiol,2015,5(4):1841-1875.
[16] Wall ST,Walker JC,Healy KE,et al. Theoretical impact of the injection of material into the myocardium:a finite element model simulation[J]. Circulation,2006,114(24):2627-2635.
[17] Matsumura Y,Zhu Y,Jiang H,et al. Intramyocardial injection of a fully synthetic hydrogel attenuates left ventricular remodeling post myocardial infarction[J]. Biomaterials,2019,217:119289.
[18] Dorsey SM,Haris M,Singh A,et al. Visualization of injectable hydrogels using chemical exchange saturation transfer MRI[J]. ACS Biomater Sci Eng,2015,1(4):227-237.
[19] Sabbah HN,Wang M,Gupta RC,et al. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure[J]. JACC Heart Fail,2013,1(3):252-258.
[20] Chow A,Stuckey DJ,Kidher E,et al. Human induced pluripotent stem cell-derived cardiomyocyte encapsulating bioactive hydrogels improve rat heart function post myocardial infarction[J]. Stem Cell Reports,2017,9(5):1415-1422.
[21] Efraim Y,Sarig H,Cohen Anavy N,et al. Biohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarction[J]. Acta Biomater,2017,50:220-233.
[22] Ifkovits JL,Tous E,Minakawa M,et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model[J]. Proc Natl Acad Sci U S A,2010,107(25):11507-11512.
[23] Lee LC,Wall ST,Klepach D,et al. Algisyl-LVR? with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart[J]. Int J Cardiol,2013,168(3):2022-2028.
[24] Frey N,Linke A,Süselbeck T,et al. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction:a first-in-man study[J]. Circ Cardiovasc Interv,2014,7(6):806-812.
[25] Wang RM,Christman KL. Decellularized myocardial matrix hydrogels:in basic research and preclinical studies[J]. Adv Drug Deliv Rev,2016,96:77-82.
[26] Anker SD,Coats AJ,Cristian G,et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)[J]. Eur Heart J,2015,36(34):2297-2309.
[27] Mann DL,Lee RJ,Coats AJ,et al. One-year follow-up results from AUGMENT-HF:a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure[J]. Eur J Heart Fail,2016,18(3):314-325.
[28] Rao SV,Zeymer U,Douglas PS,et al. A randomized,double-blind,placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction:Rationale and design of the PRESERVATION I tr ial[J]. Am Heart J,2015,170(5):929-937.
[29] Rao SV,Zeymer U,Douglas PS,et al. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction[J]. J Am Coll Cardiol,2016,68(7):715-723.
[30] Yang C,Tibbitt MW,Basta L,et al. Mechanical memory and dosing influence stem cell fate[J]. Nat Mater,2014,13(6):645-652.
[31] Heras-Bautista CO,Katsen-Globa A,Schloerer NE,et al. The influence of physiological matrix conditions on permanent culture of induced pluripotent stem cell-derived cardiomyocytes[J]. Biomaterials,2014,35(26):7374-7385.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(8):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[11]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[12]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(8):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
[13]陈广 文英 蒋学俊.可注射水凝胶在心肌梗死中的应用与进展[J].心血管病学进展,2023,(1):62.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.015]
CHEN Guang,WEN Ying,J IANG Xuejun.Application and Progress of Injectable Hydrogel in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2023,(8):62.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.015]
[14]韩冰 来春林.黑色素瘤缺乏因子2炎症小体在心血管疾病中的研究进展[J].心血管病学进展,2023,(11):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]
HAN Bing,LAI Chunlin.Absent In Melanoma 2 Inflammasome in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(8):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]
[15]王昕瑜 张婷婷 邢邯英 王忠丽 郭艺芳.miR-21在心肌缺血损伤相关信号通路中的作用[J].心血管病学进展,2024,(11):998.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.009]
WANG Xinyu,ZHANG Tingting,XING Hanying,et al.The Effect of miR-21 in Signaling Pathway Associated with Myocardical Ischemia Injury[J].Advances in Cardiovascular Diseases,2024,(8):998.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.009]